Navigation Links
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)
Date:12/11/2008

LONDON, Dec. 11 /PRNewswire-FirstCall/ -- On December 11, 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) - including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee - completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs). The committees concluded that the benefits of AstraZeneca's SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), a combination LABA/Inhaled Corticosteroid (ICS) medication, outweigh the risks in adult and adolescent asthma patients.

Howard Hutchinson, M.D., Chief Medical Officer of AstraZeneca, said, "The safety and efficacy of SYMBICORT have been demonstrated in numerous clinical trials and from extensive post-marketing use around the world. We are pleased that the joint advisory committees' recommendation confirms our view on the positive benefit-risk profile of SYMBICORT."

The FDA frequently convenes advisory committee meetings to obtain independent expert guidance and recommendations on clinical matters. While the FDA is not required to follow this guidance, the agency usually takes the advice into consideration when rendering its final decisions on pending applications and other public health matters.

About SYMBICORT in the U.S.

SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) is approved in over 100 countries for the long-term maintenance treatment of asthma and is available in two different inhalers, SYMBICORT TURBUHALER and in the U.S. as SYMBICORT pMDI.

SYMBICORT is a combination therapy indicated in the U.S. for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT should not be used in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... a webcast conference call to report its second quarter ... company,s business and outlook on Thursday, August 7, 2014 ... market. The call can be accessed ... five minutes prior to the start of the call ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... BUENA, N.J. , July 24, 2014 ... New Jersey based specialty generic pharmaceutical company, ... resignation from its Board of Directors.  Mr. Finio has ... company, and under the terms of his acceptance of ... continue in his role as Director for IGI Laboratories, ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... , July 30 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, today announced that on July ... LLC, stating that PharmAthene is not in compliance with the continued ... NYSE Amex Company Guide, because it has stockholders, equity of less ...
... 30 Conatus Pharmaceuticals Inc. announced today that Conatus ... disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver ... , ... Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer ...
Cached Medicine Technology:PharmAthene Provides Update on NYSE Amex Listing Compliance Plan 2PharmAthene Provides Update on NYSE Amex Listing Compliance Plan 3Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
(Date:7/26/2014)... Louisville, Kentucky (PRWEB) July 26, 2014 ... concussions on the playing field; however, concussions ... on-the-job injuries. The occupations with the highest risk ... workers ,     Firefighters ,     Police officers ... dock workers ,     Delivery personnel ...
(Date:7/26/2014)... 2014 According to the "Get Rid ... is a comprehensive guide that provides readers with safe ... This book also teaches them how to fade dark ... in their own home for drastic results. , ... Naturally" book includes step-by-step tutorials and product recommendations for ...
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist that ... dentistry, clear braces and much more, has just announced ... Derby. The new practice, which is scheduled to open ... Littleover, Derby. Patients may already pre-register for the limited ... practice, which is headed by Invisalign specialist and cosmetic ...
(Date:7/25/2014)... 2014 Deep Research Report on ... Industry” is a professional and in-depth research report ... market. The report provides basic Laser Scanning Confocal ... definition, classification, application, and industry chain structure ... international market analysis, including China’s domestic market as ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 American motor ... or unexpected collisions can pay higher premiums for vehicle ... its local insurer network to provide SR22 insurance for ... , The different coverage network of local agencies ... expanded the search platform now publicly available for any ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2
... Ever dream of shifting around body fat to flatten ... Or maybe blocking that ample fat? According to ... reality. ,The study, published online in Nature ... treatment of diseases associated with human obesity," the Georgetown ...
... a unique opportunity for superstition and marketing to come together: ... and Live Earth concerts as well as the proclamation of ... ,"Number 7 has a magic sacred side and the ... sevens could bring an extra dose of good fortune. ...
... marketing authorization for INVEGA(TM) (paliperidone prolonged release ... treatment of schizophrenia. This once-daily medication ... the active ingredient in INVEGA - through ... clinical trials, INVEGA demonstrated significant efficacy as ...
... shown that female mice tend to create new brain cells ... that outlines how chemical messages may shape their choice of ... at the university looked at the effects of sex pheromones, ... choose their mates, on the brains of female mice. They ...
... studies have highlighted the adverse effects of computer games on ... can actually be good for children. ,According ... other give children a chance to learn about the opposite ... ,The study by researchers from Brunel University found ...
... have revealed that an 'early warning signal' in the brain ... discovered a mechanism in the brain that reacts in just ... errors in the past. ,Earlier research has ... initially make incorrect predictions than from things for which our ...
Cached Medicine News:Health News:Stressed Mice may Hold Clue to How Fat is Stored: Study 2Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 2Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 3Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 4Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 5Health News:Male Pheromones Build Brain Cells in Female Mice 2Health News:Exposure to Computer Games can Be 'good' for Kids, Says New Study 2Health News:This is How We Learn from Our Past Mistakes 2
... is a sterile, pre-shaped, three-dimensional device constructed ... mesh cylinder to a circular underlay patch.,The ... and innovative design combines the three most ... the repair of inguinal hernias. ,Its Onlay ...
Surgisis Inguinal Hernia Matrix is implanted to reinforce soft tissues in the inguinal floor to repair inguinal hernias. Supplied sterile in peel-open packages. Intended for one-time use....
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... of 532 nm lasers are distinguished from ... solid-state design. A compact and sealed ... and reliable for a broad range of ... hemoglobin and an adjustable pulse length, the ...
Medicine Products: